Structured Review

Abcam anti synpo
Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for <t>SYNPO</t> and VIM while <t>NCAM</t> did not exhibit any change between different groups. c Representative immunoblots of selected proteins using individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-hoc Bonferroni tests) * p
Anti Synpo, supplied by Abcam, used in various techniques. Bioz Stars score: 95/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti synpo/product/Abcam
Average 95 stars, based on 2 article reviews
Price from $9.99 to $1999.99
anti synpo - by Bioz Stars, 2022-09
95/100 stars

Images

1) Product Images from "An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias"

Article Title: An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias

Journal: Molecular Brain

doi: 10.1186/s13041-017-0316-9

Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for SYNPO and VIM while NCAM did not exhibit any change between different groups. c Representative immunoblots of selected proteins using individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-hoc Bonferroni tests) * p
Figure Legend Snippet: Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for SYNPO and VIM while NCAM did not exhibit any change between different groups. c Representative immunoblots of selected proteins using individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-hoc Bonferroni tests) * p

Techniques Used: Western Blot, Expressing

2) Product Images from "Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia"

Article Title: Novel pathophysiological markers are revealed by iTRAQ-based quantitative clinical proteomics approach in vascular dementia

Journal: Journal of Proteomics

doi: 10.1016/j.jprot.2014.01.011

Post-proteomic validation of the selected proteins using individual patients from control and VaD groups by WB analysis. Equal amount of protein was loaded as measured by the 2D Quant kit. A) Representative immunoblots showing the protein levels in B21 area of all twenty patients (n = 10 per group). Details of the patients can be found in the Supplemental Table 1. ACTB was used as a loading control. B) Bar chart of densitometric analysis for comparing the protein expression levels by the statistical analysis. SOD1 and NCAM were significantly increased whereas ATP5A was reduced significantly in the VaD brain. Trends were observed for SYNPO, HSPA4, VADC1, ferritin, PEA15 and ICAM5 without reaching a statistical significance. Data was presented as mean ± SEM (n = 10), where * p
Figure Legend Snippet: Post-proteomic validation of the selected proteins using individual patients from control and VaD groups by WB analysis. Equal amount of protein was loaded as measured by the 2D Quant kit. A) Representative immunoblots showing the protein levels in B21 area of all twenty patients (n = 10 per group). Details of the patients can be found in the Supplemental Table 1. ACTB was used as a loading control. B) Bar chart of densitometric analysis for comparing the protein expression levels by the statistical analysis. SOD1 and NCAM were significantly increased whereas ATP5A was reduced significantly in the VaD brain. Trends were observed for SYNPO, HSPA4, VADC1, ferritin, PEA15 and ICAM5 without reaching a statistical significance. Data was presented as mean ± SEM (n = 10), where * p

Techniques Used: Western Blot, Expressing

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Abcam anti synaptopodin antibody
    Glucose promoted podocyte proliferation in a marked time- and dose-dependent manner. (A) Podocytes were cultured at 37°C for 12, 24 and 48 h. The <t>synaptopodin</t> expression was detected using immunofluorescence assay. The cells were visualized under fluorescence microscopy. Blue and red fluorescence represents the nucleus and synaptopodin, respectively. (B) MTT assay was performed to measure the proliferation of podocytes treated with PBS and glucose at 0, 5, 10, 20, 40, 60, 80 and100 mM for 6, 12, 24 and 48 h. OD, optical density; A, absorbance.
    Anti Synaptopodin Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti synaptopodin antibody/product/Abcam
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti synaptopodin antibody - by Bioz Stars, 2022-09
    93/100 stars
      Buy from Supplier

    90
    Abcam mouse monoclonal anti synaptopodin primary antibody
    Letrozole and Aβ 1–42 reduce synaptic proteins. (a) Representative 3D reconstructions of dendritic segments from sister cultures that were treated with either control, Aβ 1–42 (1 μ M), and letrozole (1 μ m) or Aβ 1–42 + letrozole (1 μ m) for 24 or 72 hours and immunostained for synaptophysin (white) and <t>synaptopodin</t> (red). Scale bar, 2 μ m. (b) Quantification of the densities of synaptopodin-positive puncta following treatments. There is a significant decrease in synaptopodin puncta after 24 and 72 hours of Aβ 1–42 , letrozole or Aβ 1–42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptopodin puncta was significantly lower in letrozole and Aβ 1–42 + letrozole-treated cultures compared to Aβ 1–42 alone. When synaptopodin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease only in letrozole and Aβ 1–42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μ m from 12 cells in 4 cultures; Aβ 1–42 , n = 633 μ m of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μ m of dendrite from 10 cells in 4 cultures; Aβ 1–42 + letrozole, n = 1007 μ m of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μ m from 10 cells in 3 cultures; Aβ 1–42 , n = 472 μ m of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μ m of dendrite from 9 cells in 4 cultures; Aβ 1–42 + letrozole, n = 750 μ m of dendrite from 8 cells in 4 cultures. There is a significant decrease in synaptophysin puncta after 24 and 72 hours of Aβ 1–42 , letrozole, or Aβ 1–42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptophysin puncta was significantly lower in letrozole and Aβ 1–42 + letrozole-treated cultures compared to Aβ 1–42 alone When synaptophysin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease in Aβ 1–42 , letrozole, and Aβ 1–42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μ m from 12 cells in 4 cultures; Aβ 1–42 , n = 633 μ m of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μ m of dendrite from 10 cells in 4 cultures; Aβ 1–42 + letrozole, n = 1007 μ m of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μ m from 10 cells in 3 cultures; Aβ 1–42 , n = 472 μ m of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μ m of dendrite from 9 cells in 4 cultures; Aβ 1–42 + letrozole, n = 750 μ m of dendrite from 8 cells in 4 cultures.
    Mouse Monoclonal Anti Synaptopodin Primary Antibody, supplied by Abcam, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse monoclonal anti synaptopodin primary antibody/product/Abcam
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse monoclonal anti synaptopodin primary antibody - by Bioz Stars, 2022-09
    90/100 stars
      Buy from Supplier

    90
    Abcam synaptopodin antibodies
    Effects of quercetin on HG-induced podocyte injury through the EGFR pathway. (A , B , G , H) Distribution and expression of <t>synaptopodin</t> and nephrin in podocyte through immunofluorescence. (C , D , I , J) Statistical analysis of synaptopodin, nephrin expression. (E , K) Expression of synaptopodin through western blotting. (F , L) Statistical analysis of synaptopodin protein expression. Cells were starved for 24 h and treated with normal glucose, high glucose, DMSO, quercetin, AG1478 or Q40 + AG1478 for 24 h. Data were expressed as mean ± SEM, n = 3. ## p
    Synaptopodin Antibodies, supplied by Abcam, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/synaptopodin antibodies/product/Abcam
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    synaptopodin antibodies - by Bioz Stars, 2022-09
    90/100 stars
      Buy from Supplier

    80
    Abcam anti synpo
    Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for <t>SYNPO</t> and VIM while <t>NCAM</t> did not exhibit any change between different groups. c Representative immunoblots of selected proteins using individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-hoc Bonferroni tests) * p
    Anti Synpo, supplied by Abcam, used in various techniques. Bioz Stars score: 80/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti synpo/product/Abcam
    Average 80 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti synpo - by Bioz Stars, 2022-09
    80/100 stars
      Buy from Supplier

    Image Search Results


    Glucose promoted podocyte proliferation in a marked time- and dose-dependent manner. (A) Podocytes were cultured at 37°C for 12, 24 and 48 h. The synaptopodin expression was detected using immunofluorescence assay. The cells were visualized under fluorescence microscopy. Blue and red fluorescence represents the nucleus and synaptopodin, respectively. (B) MTT assay was performed to measure the proliferation of podocytes treated with PBS and glucose at 0, 5, 10, 20, 40, 60, 80 and100 mM for 6, 12, 24 and 48 h. OD, optical density; A, absorbance.

    Journal: Experimental and Therapeutic Medicine

    Article Title: Silence of IGFBP7 suppresses apoptosis and epithelial mesenchymal transformation of high glucose induced-podocytes

    doi: 10.3892/etm.2018.6298

    Figure Lengend Snippet: Glucose promoted podocyte proliferation in a marked time- and dose-dependent manner. (A) Podocytes were cultured at 37°C for 12, 24 and 48 h. The synaptopodin expression was detected using immunofluorescence assay. The cells were visualized under fluorescence microscopy. Blue and red fluorescence represents the nucleus and synaptopodin, respectively. (B) MTT assay was performed to measure the proliferation of podocytes treated with PBS and glucose at 0, 5, 10, 20, 40, 60, 80 and100 mM for 6, 12, 24 and 48 h. OD, optical density; A, absorbance.

    Article Snippet: The anti-synaptopodin antibody (1:600; cat. no. ab220345; Abcam) was used to incubate with the cells overnight at 4°C.

    Techniques: Cell Culture, Expressing, Immunofluorescence, Fluorescence, Microscopy, MTT Assay

    Letrozole and Aβ 1–42 reduce synaptic proteins. (a) Representative 3D reconstructions of dendritic segments from sister cultures that were treated with either control, Aβ 1–42 (1 μ M), and letrozole (1 μ m) or Aβ 1–42 + letrozole (1 μ m) for 24 or 72 hours and immunostained for synaptophysin (white) and synaptopodin (red). Scale bar, 2 μ m. (b) Quantification of the densities of synaptopodin-positive puncta following treatments. There is a significant decrease in synaptopodin puncta after 24 and 72 hours of Aβ 1–42 , letrozole or Aβ 1–42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptopodin puncta was significantly lower in letrozole and Aβ 1–42 + letrozole-treated cultures compared to Aβ 1–42 alone. When synaptopodin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease only in letrozole and Aβ 1–42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μ m from 12 cells in 4 cultures; Aβ 1–42 , n = 633 μ m of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μ m of dendrite from 10 cells in 4 cultures; Aβ 1–42 + letrozole, n = 1007 μ m of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μ m from 10 cells in 3 cultures; Aβ 1–42 , n = 472 μ m of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μ m of dendrite from 9 cells in 4 cultures; Aβ 1–42 + letrozole, n = 750 μ m of dendrite from 8 cells in 4 cultures. There is a significant decrease in synaptophysin puncta after 24 and 72 hours of Aβ 1–42 , letrozole, or Aβ 1–42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptophysin puncta was significantly lower in letrozole and Aβ 1–42 + letrozole-treated cultures compared to Aβ 1–42 alone When synaptophysin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease in Aβ 1–42 , letrozole, and Aβ 1–42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μ m from 12 cells in 4 cultures; Aβ 1–42 , n = 633 μ m of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μ m of dendrite from 10 cells in 4 cultures; Aβ 1–42 + letrozole, n = 1007 μ m of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μ m from 10 cells in 3 cultures; Aβ 1–42 , n = 472 μ m of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μ m of dendrite from 9 cells in 4 cultures; Aβ 1–42 + letrozole, n = 750 μ m of dendrite from 8 cells in 4 cultures.

    Journal: Journal of Aging Research

    Article Title: Letrozole Potentiates Mitochondrial and Dendritic Spine Impairments Induced by β Amyloid

    doi: 10.1155/2013/538979

    Figure Lengend Snippet: Letrozole and Aβ 1–42 reduce synaptic proteins. (a) Representative 3D reconstructions of dendritic segments from sister cultures that were treated with either control, Aβ 1–42 (1 μ M), and letrozole (1 μ m) or Aβ 1–42 + letrozole (1 μ m) for 24 or 72 hours and immunostained for synaptophysin (white) and synaptopodin (red). Scale bar, 2 μ m. (b) Quantification of the densities of synaptopodin-positive puncta following treatments. There is a significant decrease in synaptopodin puncta after 24 and 72 hours of Aβ 1–42 , letrozole or Aβ 1–42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptopodin puncta was significantly lower in letrozole and Aβ 1–42 + letrozole-treated cultures compared to Aβ 1–42 alone. When synaptopodin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease only in letrozole and Aβ 1–42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μ m from 12 cells in 4 cultures; Aβ 1–42 , n = 633 μ m of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μ m of dendrite from 10 cells in 4 cultures; Aβ 1–42 + letrozole, n = 1007 μ m of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μ m from 10 cells in 3 cultures; Aβ 1–42 , n = 472 μ m of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μ m of dendrite from 9 cells in 4 cultures; Aβ 1–42 + letrozole, n = 750 μ m of dendrite from 8 cells in 4 cultures. There is a significant decrease in synaptophysin puncta after 24 and 72 hours of Aβ 1–42 , letrozole, or Aβ 1–42 + letrozole treatments compared to control conditions. After 72 hours, the number of synaptophysin puncta was significantly lower in letrozole and Aβ 1–42 + letrozole-treated cultures compared to Aβ 1–42 alone When synaptophysin puncta densities were compared between 24- and 72-hour treated cultures there was a significant decrease in Aβ 1–42 , letrozole, and Aβ 1–42 + letrozole-treated cultures after 72 hours. 24 hours: control, n = total dendritic segment lengths of 1041 μ m from 12 cells in 4 cultures; Aβ 1–42 , n = 633 μ m of dendrite from 8 cells in 4 cultures; letrozole, n = 952 μ m of dendrite from 10 cells in 4 cultures; Aβ 1–42 + letrozole, n = 1007 μ m of dendrite from 10 cells in 4 cultures. 72 hours: control, n = total dendritic segment lengths of 559 μ m from 10 cells in 3 cultures; Aβ 1–42 , n = 472 μ m of dendrite from 9 cells in 4 cultures; letrozole, n = 838 μ m of dendrite from 9 cells in 4 cultures; Aβ 1–42 + letrozole, n = 750 μ m of dendrite from 8 cells in 4 cultures.

    Article Snippet: Rabbit monoclonal anti-synaptophysin primary antibody was used at 1 : 400 dilution (Zymed, CA, USA) and mouse monoclonal anti-synaptopodin primary antibody was used at 1 : 400 dilution (Abcam, MA, USA), as well.

    Techniques:

    Effects of quercetin on HG-induced podocyte injury through the EGFR pathway. (A , B , G , H) Distribution and expression of synaptopodin and nephrin in podocyte through immunofluorescence. (C , D , I , J) Statistical analysis of synaptopodin, nephrin expression. (E , K) Expression of synaptopodin through western blotting. (F , L) Statistical analysis of synaptopodin protein expression. Cells were starved for 24 h and treated with normal glucose, high glucose, DMSO, quercetin, AG1478 or Q40 + AG1478 for 24 h. Data were expressed as mean ± SEM, n = 3. ## p

    Journal: Frontiers in Pharmacology

    Article Title: Quercetin Attenuates Podocyte Apoptosis of Diabetic Nephropathy Through Targeting EGFR Signaling

    doi: 10.3389/fphar.2021.792777

    Figure Lengend Snippet: Effects of quercetin on HG-induced podocyte injury through the EGFR pathway. (A , B , G , H) Distribution and expression of synaptopodin and nephrin in podocyte through immunofluorescence. (C , D , I , J) Statistical analysis of synaptopodin, nephrin expression. (E , K) Expression of synaptopodin through western blotting. (F , L) Statistical analysis of synaptopodin protein expression. Cells were starved for 24 h and treated with normal glucose, high glucose, DMSO, quercetin, AG1478 or Q40 + AG1478 for 24 h. Data were expressed as mean ± SEM, n = 3. ## p

    Article Snippet: ERK1/2, p-ERK1/2, Bcl2, Bax and synaptopodin antibodies were purchased from Abcam (Cambridge, United Kingdom). β-actin antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, United States).

    Techniques: Expressing, Immunofluorescence, Western Blot

    Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for SYNPO and VIM while NCAM did not exhibit any change between different groups. c Representative immunoblots of selected proteins using individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-hoc Bonferroni tests) * p

    Journal: Molecular Brain

    Article Title: An iTRAQ-based proteomic analysis reveals dysregulation of neocortical synaptopodin in Lewy body dementias

    doi: 10.1186/s13041-017-0316-9

    Figure Lengend Snippet: Two-step immunoblot analysis of selected proteins. a Representative immunoblots from the pooled lysates showing the protein levels of Control, DLB, PDD and the combined ‘Dementias’ group, with GAPDH used as the loading control. b Bar chart of immunoreactivities (mean ± SEM in arbitrary units) for comparing protein expression levels (with mean control values set at 1.0). Dotted lines were drawn at ± 1.3-fold to indicate the threshold of deregulation as determined from the iTRAQ experiment. The data shows upward trends for GSTP1, PLP1 and downward trends for SYNPO and VIM while NCAM did not exhibit any change between different groups. c Representative immunoblots of selected proteins using individual subjects. Control (C), PDD (P) and DLB (D) subjects selected randomly from each group for different proteins. GAPDH was used as the loading control. d Bar chart of normalized immuno-reactivities (mean ± SEM in arbitrary units) of the proteins of interest was calculated from all subjects (21 Controls, 19 DLB, 21 PDD) selected for the iTRAQ experiment. Significant difference (one-way ANOVA followed by post-hoc Bonferroni tests) * p

    Article Snippet: Immunoblotting Immunoblotting was performed after 10% or 12% SDS-PAGE by probing with primary antibodies at the indicated dilutions: anti-GAPDH (1: 1000, mouse monoclonal; Milipore, Billerica, MA, USA), anti-COL6A3 (1:200, mouse monoclonal; Santa Cruz Biotech, Santa Cruz, CA, USA), anti-GSTP1 (1:1000, rabbit polyclonal; Abcam, Cambridge, UK), anti-FLNA (1:1000; rabbit polyclonal; Cell Signaling Technology, Danvers, MA, USA), anti-NCAM (1:10,000, rabbit polyclonal; Santa Cruz Biotech), anti-PLP1 (1:1000, rabbit polyclonal; Abcam), anti-SYNPO (1:500, rabbit polyclonal; Abcam), anti-VIM (1:1000, rabbit polyclonal; Genscript, Piscataway, NJ, USA).

    Techniques: Western Blot, Expressing